Skip to main content

Table 2 Serotype of community-acquired rotavirus cases presenting to CHOP during the 6 rotavirus epidemic seasons (1999-2000 through 2005-06)§ prior to introduction of the new rotavirus vaccines◊ by age

From: Unexpectedly high burden of rotavirus gastroenteritis in very young infants

 

0 to 5 months

6 to 11 months

12 to 17 months

18 to 23 months

≥2 years

All Ages

 

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

G1

134 (63)

182 (76)

112 (74)

90 (78)

154 (71)

672 (72)

G2

41 (19)

20 (9)

17 (11)

12 (10)

39 (18)

129 (14)

G3

3 (1)

6 (3)

5 (3)

0 (0)

3 (1)

17 (2)

G4

6 (3)

3 (1)

4 (3)

0 (0)

5 (2)

18 (2)

G8

0 (0)

1 (<1)

0 (0)

0 (0)

0 (0)

1 (<1)

G9

24 (11)

15 (6)

8 (5)

7 (6)

13 (6)

67 (7)

G12

5 (2)

11 (5)

6 (4)

6 (5)

2 (1)

30 (3)

Totals (7 seasons)

213 (100)

238 (100)

152 (100)

115 (100)

216 (100)

934 (100)

  1. n (%), number (percent) of cases in the specified age category infected with each identified rotavirus serotype.
  2. §Starting with the 1999-2000 season, ELISA-positive specimens were genotyped by reverse transcriptase-polymerase chain reaction at Merck Research Laboratories when the quantity of stool specimen permitted (1, 33). Designation of G-serotype was based on nucleic acid homology in comparison with a database of sequences of known serotypes.
  3. â—ŠA tetravalent rotavirus vaccine had been transiently marketed in the United States in 1998-99.